Corrections for Macugen Briefing Document (NDA 21-756).

Page 18 of briefing document:

Primary Efficacy Results – PP population observed cases only– Study 1003

Number of Patients (%)		**0.3 mg**	**1 mg**	**3 mg**	**Sham**
Responders[1]	Month 3	122 (87.8%) *N=139*	**131 (92.9%)** *N= 141*	122 (86.5%) *N= 141*	120 (82.8%) *N= 145*
	Month 6	**110 (85.3%)** *N= 129*	**125 (86.8%)** *N= 144*	116 (82.3%) *N= 141*	101 (69.7%) *N= 145*
	Month 9	**103 (78.3%)** *N= 131*	115 (79.9%) *N= 144*	110 (79.1%) *N= 139*	93 (66%) *N= 141*
	Month 12	98 (73.7%) p=0.01 *N= 133*	105 (75.5%) p=0.005 *N= 139*	90 (66.7%) *N= 135*	82 (58.6%) *N= 140*

[1] Patients who lost < 15 letters of vision. Note: Patients who lost < 15 letters of vision from baseline to 54 weeks is the primary efficacy endpoint

[2] 3 mg dose was omitted from statistical analysis prior to unmasking data

Page 24 of briefing document:



Page 25 briefing document:



Page 34 briefing document:



	baseline	week 6	week 12	week 18	week 24	week 30	week 36	week 42	week 48	week 54
0.3 mg	52.5	50.5	49.4	47.9	47.5	46.8	45.8	45.2	45	44.2
1 mg	50.5	48.7	46.8	45.3	44.1	42.9	42.9	42	41.5	41.9
3 mg	52.1	50.1	46.8	45.3	43.1	41.9	41.6	40.8	39.7	39.6
sham	54	49.2	46.7	43.7	42.4	39.5	38.7	37.8	37.1	36.6